India, July 14 -- In the first clinical trial of its kind, researchers from the Medical University of South Carolina and Georgetown University found that a specially formulated medicine containing Tetrahydrocannabinol and Cannabidiol, two active compounds found in cannabis (marijuana), helped reduce agitation in older adults with dementia.
The study, called the LiBBY trial (Life's End Benefits of Cannabidiol and Tetrahydrocannabinol), included 120 participants with Alzheimer's disease or other forms of dementia. All participants were eligible for hospice care and were experiencing agitation. The trial was conducted at 10 medical centres across the United States, with researchers visiting participants in their homes or care facilities.
The...